 | Up a level |
Banz, Yara; Hess, Otto M; Meier, Pascal; Korchagina, Elena Y; Gordeeva, Elena A; Robson, Simon C; Gajanayake, Thusitha; Csizmadia, Eva; Mettler, Daniel; Haeberli, André; Bovin, Nicolai V; Rieben, Robert (2012). Evaluation of multimeric tyrosine-O-sulfate as a cytoprotectant in an in vivo model of acute myocardial infarction in pigs. Cardiology, 121(1), pp. 59-70. Basel: Karger 10.1159/000336485
Künzli, Beat M; Bernlochner, Maria-Isabell; Rath, Stephan; Käser, Samuel; Csizmadia, Eva; Enjyoji, Keiichi; Cowan, Peter; d'Apice, Anthony; Dwyer, Karen; Rosenberg, Robert; Perren, Aurel; Friess, Helmut; Maurer, Christoph A; Robson, Simon C (2011). Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic signalling, 7(2), pp. 231-41. Dordrecht: Springer 10.1007/s11302-011-9228-9
Sheth, Sunil; Bleibel, Wissam; Thukral, Chandrashekhar; A-Rahim, Yousif; Beldi, Guido; Csizmadia, Eva; Robson, Simon C (2009). Heightened NTPDase-1/CD39 expression and angiogenesis in radiation proctitis. Purinergic signalling, 5(3), pp. 321-6. Dordrecht: Springer 10.1007/s11302-009-9154-2
Banz, Yara; Hess, Otto M; Robson, Simon C; Csizmadia, Eva; Mettler, Daniel; Meier, Pascal; Haeberli, André; Shaw, Sidney; Smith, Richard A; Rieben, Robert (2007). Attenuation of myocardial reperfusion injury in pigs by Mirococept, a membrane-targeted complement inhibitor derived from human CR1. Cardiovascular research, 76(3), pp. 482-93. Oxford: Elsevier Ltd. 10.1016/j.cardiores.2007.07.016
Banz, Yara; Hess, Otto M; Robson, Simon C; Mettler, Daniel; Meier, Pascal; Haeberli, André; Csizmadia, Eva; Korchagina, Elena Y; Bovin, Nicolai V; Rieben, Robert (2005). Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury. European Heart Journal, 26(21), pp. 2334-43. Oxford: Oxford University Press 10.1093/eurheartj/ehi421
Sun, Xiaofeng; Wu, Yon; Ogawa, Mika; Enjoyji, Keiichi; Csizmadia, Eva; Beldi, Guido; Robson, Simon C (2007). Deletion of CD39 inhibits development of metastatic liver cancer. Hepatology, 46(4S), 690A-690A. Wiley Interscience 10.1002/hep.22020
